Investor profile
Seroba Life Sciences has backed 9 European tech companies across 10 funding rounds between 2017 and 2025, joining rounds totalling €272M. Most active in Healthtech. Data as of 6 Aug 2026.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Complement Therapeutics | Germany | 1 | €72M |
| Coave Therapeutics | France | 2 | €53M |
| Quanta | UK | 1 | €42M |
| Medlumics | Spain | 1 | €34M |
| Storm Therapeutics | UK |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Complement Therapeutics | Series A | €72M | 2023-04 |
| Quanta | Series C | €42M | 2019-07 |
| Medlumics | Series B | €34M | 2017-03 |
| Coave Therapeutics |
| 1 |
| €28M |
| Sibylla Biotech | Italy | 1 | €23M |
| Palliare | Ireland | 1 | €8.0M |
| Shorla Pharma | Ireland | 1 | €7.4M |
| Deciphex | Ireland | 1 | €3.9M |
| Series A |
| €32M |
| 2025-01 |
| Storm Therapeutics | Series B | €28M | 2022-12 |
| Sibylla Biotech | Series A | €23M | 2022-10 |
| Coave Therapeutics | Series B | €21M | 2021-07 |
| Palliare | Other | €8.0M | 2021-07 |
| Shorla Pharma | Series A | €7.4M | 2020-03 |
| Deciphex | Series B | €3.9M | 2023-01 |
